Back

Impact of right ventricular dimension and function on outcomes in patients undergoing cardiac resynchronization therapy

12 May 2024 (10:00 - 10:45)
Organised by: Logo
Congress Presentation Part of: Chronic heart failure - treatment 4 Cardiac Resynchronisation Therapy (CRT) HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Francisco Rodrigues Santos

Hospital Sao Teotonio, Viseu (Portugal)

6 More presentations in this session

Presentation thumbnail
Elevating patient care: effective screening strategies to detect pacemaker induced cardiomyopathy
Doctor C. Seyani (Southampton, GB)
Abstract Slides Video
Presentation thumbnail
Timing CRT implantation in heart failure: an analysis on LVEF recovery and device implantation
Doctor M. Raposo (Lisbon, PT)
Abstract Slides Video
Presentation thumbnail
Optimizing CRT response in atrial fibrillation: unraveling the role of mitral valve regurgitation reduction for enhanced patient outcomes
Mr A. Rocha De Almeida (Evora, PT)
Abstract Slides Video
Presentation thumbnail
The relationship between handgrip strength and peak oxygen uptake in cardiovascular resynchronisation therapy patients
Mr M. Wickens (Leeds, GB)
Abstract Slides Video
Presentation thumbnail
Impact of heart failure chronicity on long-term outcomes after cardiac resynchronization therapy
Mr E. Grama (Barcelona, ES)
Abstract Slides Video

Access the full session

Session thumbnail
Chronic heart failure - treatment 4

The Event

Event poster

Heart Failure 2024

12 May 2024 10:00 CET
You may be interested in
thumbnail
Congress Presentation
Improved right ventricular systolic function after cardiac resynchronization therapy in heart failure patients
thumbnail
Congress Presentation
Right ventricular systolic pressure is an independent risk factor of all-cause death and inappropriate therapies in patients with implanted CRT-D
thumbnail
Congress Presentation
Prognostic value of tricuspid regurgitation and right ventricular dysfunction after cardiac resynchronization therapy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources